These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
4. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Bodey B; Bodey B; Siegel SE; Kaiser HE Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379 [TBL] [Abstract][Full Text] [Related]
6. Future prospects of monoclonal antibodies as magic bullets in immunotherapy. Maleki LA; Baradaran B; Majidi J; Mohammadian M; Shahneh FZ Hum Antibodies; 2013; 22(1-2):9-13. PubMed ID: 24284304 [TBL] [Abstract][Full Text] [Related]
7. Systemic immunotoxin therapy of cancer: advances and prospects. Wawrzynczak EJ Br J Cancer; 1991 Oct; 64(4):624-30. PubMed ID: 1911210 [No Abstract] [Full Text] [Related]
8. Overview of monoclonal antibodies in the diagnosis and therapy of cancer. Vaickus L; Foon KA Cancer Invest; 1991; 9(2):195-209. PubMed ID: 1863875 [TBL] [Abstract][Full Text] [Related]
9. Rationale for clinical use of immunotoxins in cancer and autoimmune disease. Byers VS; Baldwin RW Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344 [TBL] [Abstract][Full Text] [Related]
10. Prospects for immunotoxin therapy of non-Hodgkin's lymphoma. Grossbard ML; Fidias P Clin Immunol Immunopathol; 1995 Aug; 76(2):107-14. PubMed ID: 7614729 [TBL] [Abstract][Full Text] [Related]
11. Immunotoxin therapy of malignant melanoma. Spitler LE Med Oncol Tumor Pharmacother; 1986; 3(3-4):147-52. PubMed ID: 3543527 [TBL] [Abstract][Full Text] [Related]
12. Recombinant antibodies in cancer therapy. Nayeem MS; Khan RH Curr Protein Pept Sci; 2006 Apr; 7(2):165-70. PubMed ID: 16611141 [TBL] [Abstract][Full Text] [Related]
13. Immunotoxins in cancer therapy: Review and update. Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218 [TBL] [Abstract][Full Text] [Related]
14. Enhancement of immunotoxin activity using chemical and biological reagents. Wu M Br J Cancer; 1997; 75(9):1347-55. PubMed ID: 9155057 [TBL] [Abstract][Full Text] [Related]
15. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. Zovickian J; Johnson VG; Youle RJ J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171 [TBL] [Abstract][Full Text] [Related]
16. Targeted antibodies in the treatment of lymphomas. Falini B; Terenzi A; Liso A; Flenghi L; Solinas A; Pasqualucci L Cancer Surv; 1997; 30():295-309. PubMed ID: 9547998 [TBL] [Abstract][Full Text] [Related]
17. [Use of monoclonal antibodies in the immunotherapy of neoplasms]. Robak T Przegl Lek; 1989; 46(4):420-6. PubMed ID: 2672121 [No Abstract] [Full Text] [Related]
18. [Immunotoxin: from the idea of "magic bullets" to clinical applications]. Engert A; Thorpe P Med Klin (Munich); 1990 Sep; 85(9):555-60. PubMed ID: 2233614 [No Abstract] [Full Text] [Related]
19. Immunotoxin: A new tool for cancer therapy. Allahyari H; Heidari S; Ghamgosha M; Saffarian P; Amani J Tumour Biol; 2017 Feb; 39(2):1010428317692226. PubMed ID: 28218037 [TBL] [Abstract][Full Text] [Related]
20. Current status of antitumor therapy with monoclonal antibodies. Scheinberg DA; Houghton AN Oncology (Williston Park); 1987 May; 1(3):31-40. PubMed ID: 3079479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]